Showing results (21-30 of 871) with videos related to
Sort By:
Pageof 88
Plos One|July 28, 2017
Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis-The PaSiMS II studyGabriel Bsteh, Rainer Ehling, Lisa-Maria Walchhofer, et al.Journal of Neuroimmunology|December 4, 2003
Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disordersMarkus Reindl, Sabrina Khantane, Rainer Ehling, et al.Journal of Neuroimmunology|August 27, 2010
Natalizumab treatment reduces endothelial activity in MS patientsAlban Millonig, Harald Hegen, Franziska Di Pauli, et al.Fluids and Barriers of the CNS|October 28, 2011
Fibrinogen is not elevated in the cerebrospinal fluid of patients with multiple sclerosisRainer Ehling, Franziska Di Pauli, Peter Lackner, et al.Nature Reviews. Neurology|August 15, 2022
Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex conceptRomana Höftberger, Hans Lassmann, Thomas Berger, et al.Current Opinion in Neurology|March 2, 2017
Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they?Markus Reindl, Sven Jarius, Kevin Rostasy, et al.Expert Opinion on Medical Diagnostics|March 16, 2013
Diagnostic biomarkers in multiple sclerosisBettina Kuenz, Florian Deisenhammer, Thomas Berger, et al.Die Rehabilitation|December 14, 2022
[Psychometric Evaluation of the 'German Neurological Fatigue Index for Multiple Sclerosis (NFI-MS-G)' in a Sample of Rehabilitation Patients with Multiple Sclerosis]Barbara Seebacher, Mike C Horton, Markus Reindl, et al.Nature Reviews. Neurology|June 26, 2013
The spectrum of MOG autoantibody-associated demyelinating diseasesMarkus Reindl, Franziska Di Pauli, Kevin Rostásy, et al.BMC Neurology|April 18, 2021
German translation, cultural adaptation and validation of the unidimensional self-efficacy scale for multiple sclerosisBarbara Seebacher, Roger J Mills, Markus Reindl, et al.Pageof 88